REPL

Replimune Group, Inc., headquartered in Woburn, Massachusetts, is at the forefront of biotechnology, specializing in the development of oncolytic immunotherapies aimed at revolutionizing cancer treatment. Utilizing its proprietary Immuno-Oncology platform, the company targets cancer cells with precision while enhancing the body's immune response against tumors. Replimune's advancing clinical programs demonstrate the potential effectiveness of its innovative therapies, establishing it as a key player in the dynamic oncology landscape. With a strong commitment to transforming cancer care, Replimune is well-positioned for significant growth and impact in the industry.